Poster Display & Cocktail
42P - The establishment of a large tumor organoid biobank using a well characterized/annotated patient-derived xenograft (PDX) library to enable drug discovery and translational research
Date
02 Mar 2020Session
Poster Display & CocktailPresenters
Ludovic BourreCitation
Annals of Oncology (2020) 31 (suppl_1): S17-S18. 10.1016/annonc/annonc81
Authors
L. Bourre, X. Xu, L. Shang, L. Wang, C. Li, Y. Liu, P. Han, Z. Sun, Y. Qu, L. Zhang, B. Chen, D. Ouyang, Y. Huang, H. LiAuthor affiliations
- Crown Bioscience Inc., 92127 - San Diego/US
Resources
Resources from the same session
5P - Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents
Presenter: Paolo Tarantino
Session: Poster Display & Cocktail
Resources:
Abstract
6P - Targeting leukemic stem cells using humanized chimeric immunotoxin
Presenter: Madhumathi Jayaprakasam
Session: Poster Display & Cocktail
Resources:
Abstract
7P - Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms
Presenter: Guillermo Prado
Session: Poster Display & Cocktail
Resources:
Abstract
10P - In vitro and in vivo cytolethal and antitumor effects of a novel fusion protein targeting IL-24 toward breast cancer cells
Presenter: Ali Jahanian-Najafabadi
Session: Poster Display & Cocktail
Resources:
Abstract
11P - Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Eric Angevin
Session: Poster Display & Cocktail
Resources:
Abstract
12P - IL-18 improves the anti-cancer immunity of human gamma delta T cells against prostate cancer
Presenter: Mohanad Nada
Session: Poster Display & Cocktail
Resources:
Abstract
13P - A mitigation of breast cancer-induced immune-suppressive tumor microenvironment through curbing miR-155/IL-10/TNF-α loop using a novel quercetin derivative
Presenter: Rana Youness
Session: Poster Display & Cocktail
Resources:
Abstract
14P - Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients
Presenter: Eduardo Castanon Alvarez
Session: Poster Display & Cocktail
Resources:
Abstract
20P - Interim safety and efficacy results of a phase II clinical trial on trametinib and low-dose dabrafenib in patients with advanced BRAFV600 wild-type melanoma
Presenter: Gil Awada
Session: Poster Display & Cocktail
Resources:
Abstract
21P - OX401, a new generation of PARP-interfering drug for cancer treatment
Presenter: Wael Jdey
Session: Poster Display & Cocktail
Resources:
Abstract